Insider Purchases: Inside the Buy

Tag: dividend growth investing

Illustration depicting Abbott Laboratories as a futuristic healthcare city with FreeStyle Libre glucose sensors, cancer diagnostics trains labeled Cologuard and Cancerguard, happy doctors and patients, and a giant Dividend King castle.

🩺 Abbott Laboratories (ABT) Stock Analysis: Can a Dividend King Turn Exact Sciences Into Its Next Growth Engine?

Abbott Laboratories may not be flashy, but the healthcare giant combines insider buying, a growing oncology diagnostics platform, the dominant FreeStyle Libre franchise, and more than a century of dividend payments. With shares trading near 16x forward earnings, investors may be looking at a classic Growth at a Reasonable Price opportunity.

Read entire article

Tags: Abbott Laboratories, Abbott stock analysis, AbbottLaboratories, ABT, ABT stock, buy or sell ABT, cancer diagnostics, Cologuard, diagnostics stocks, dividend growth investing, Dividend King stocks, DividendKings, Exact Sciences acquisition, ExactSciences, featured-insiders, Frédéric Marsanne, FreeStyle Libre, FreeStyleLibre, FUNanc1al, GARP investing, healthcare innovation, healthcare stocks, hub-insiders, insider buying, InsiderBuying, medical devices, MedicalDevices, oncology investing, PhilipBoudreau, risks buying ABT, value investing, ValueInvesting, why buy ABT
FUNanc1al-style scene showing a massive medieval stone castle perched atop a mountain of insurance policies. Instead of defending against dragons, the castle collects golden fee coins flowing through pipelines from homeowners, cars, and businesses below.

🦅 Erie Indemnity (ERIE): The Hidden Fee Castle Behind an 11-Day Short Squeeze Setup

Erie Indemnity isn't a traditional insurer. It collects fees rather than assuming most underwriting risk, creating one of the most unique business models in financial services. After a rare $1.4 million insider purchase, a 59% decline from all-time highs, and nearly 12 days-to-cover short interest, investors may want another look at this Dividend Aristocrat.

Read entire article

Tags: buy or sell ERIE, CapitalLight, CarpeDiem, compounders, dividend aristocrat, dividend growth investing, dividend investing, DividendAristocrat, ERIE, erie indemnity, erie insurance, erie stock, ErieIndemnity, financial stocks, fred marsanne, funanc1al, insider buying, InsiderBuying, insurance industry, insurance stocks, InsuranceBrokers, nasdaq erie, passive income, quality stocks, risks buying ERIE, short squeeze stocks, ShortSqueeze, stock analysis, value investing, ValueInvesting, why buy ERIE